Management of NSAID/aspirin-induced small intestinal damage by GI-sparing NSAIDs, anti-ulcer drugs and food constituents

Current Medicinal Chemistry

Volumn 19, Issue 1, 2012, Pages 82-89

  Satoh, H ^a   Takeuchi, K ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Aspirin; Diclofenac; Indomethacin; Intestinal ulcer; NO NSAID; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; ADZ 3582; ATB 346; DICLOFENAC; IBUPROFEN; INDOMETACIN; IRSOGLADINE MALEATE; LACTOFERRIN; LAFUTIDINE; LANSOPRAZOLE; METRONIDAZOLE; MISOPROSTOL; NAPROXCINOD; NAPROXEN; NAPROXEN DERIVATIVE; NCX 530; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHOSPHATIDYLCHOLINE; POLAPREZINC; PROBIOTIC AGENT; PROSTAGLANDIN; REBAMIPIDE; ROXATIDINE; ROXATIDINE ACETATE; TEPRENONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTICLE; BLOOD PRESSURE; CELL DAMAGE; DIARRHEA; DIETARY FIBER; DIGESTIVE SYSTEM INJURY; DRUG EFFICACY; ENTERITIS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GASTROSCOPY; HUMAN; INTESTINAL BLEEDING; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; NONHUMAN; OSTEOARTHRITIS; PILOT STUDY; RHEUMATOID ARTHRITIS; ULCER HEALING; URINARY EXCRETION;

EID: 84857604214     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803413980     Document Type: Article

References (81)

1. Graham, D.Y.; Opekum, A.R.; Willingham, F.F.; Qureshi, WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin. Gastroenterol. Hepatol., 2005, 3, 55-59. (Pubitemid 40092944)
2. Maiden, L.; Thjodleifsson, B.; Theodors, A.; Gonzalez, J.; Bjarnason, I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005, 128, 1172-1178.
3. Goldstein, J.L.; Eisen, G.M.; Lewis, B.; Gralnek, I.M.; Zlotnick, S.; Fort, J.G. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin. Gastroent. Hepatol., 2005, 3, 133-141. (Pubitemid 40220308)
4. Goldstein, J.L.; Eisen, G.M.; Lewis, B.; Gralnek, M.; Aisenberg, J.; Bhadra, P.; Berger, M.F. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment. Pharmacol. Ther., 2007, 25, 1211-1222. (Pubitemid 46650300)
5. Matsumoto, T.; Kudo, T.; Esaki, M.; Yano T.; Yamamoto, H.; Sakamoto, C.; Goto, H.; Nakase, H.; Tanaka, S.; Matsui, T.; Sugano, K.; Iida, M. Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-baloon endoscopy: a Japanese multicenter study. Scand. J. Gastroenterol., 2008, 43, 490-496.
6. Takeuchi, K.; Tanaka, A.; Kato, S.; Amagase, K.; Satoh, H. Role of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. Clin. Chim. Acta, 2010, 411, 459-466.
7. Wallace, J.L, McKnight, W.; Reuter, B.K.; Vergnolle, N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyc.; looxygenase 1 and 2. Gastroenterology, 2000, 119, 706-714.
8. Tanaka, A.; Hase. S.; Miyazawa, T.; Ohno, R.; Takeuchi, K. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal antiinflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J. Pharmacol. Exp. Ther., 2002, 303, 1248-1254. (Pubitemid 35424411)
9. Sigthorsson, G.; Simpson, R.J.; Walley, M.; Anthony, A.; Foster, R.; Hotz-Behoftsitz, C., Palizban, A.; Pombo, J.; Watt, J.; Morham, S.G.; Bjarnason, I. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal antiinflammatory drug enteropathy in mice. Gastroenterology 2002, 122, 1913-1923.
10. Fitzgerald, G.A. Coxibs and cardiovascular disease. N. Engl. J. Med., 2004, 351, 1709-1711.
11. Maiden, L.; Thjodleifsson, B.; Seigal, A.; Bjarnason, I.I.; Scott D.; Birggison, S.; Bjarnason, I. Long term effects of nonsteroidal antiinflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: A cross-sectional capsule enteroscopy study. Clin. Gastroenterol. Hepatol., 2007, 5, 1040-1045.
12. Leung, W.K.; Bjarnason, I.; Wong, V.W.; Sung, J.J.; Chan, F.K. Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet, 2007, 369, 614. (Pubitemid 46241446)
13. Endo, H.; Hosono, K.; Inamori, M.; Kato, S.; Nozaki, Y.; Yoneda, K.; Akiyama, T.; Fujita, K.; Takahashi, H.; Yoneda, M.; Abe, Y.; Kirikoshi, H.; Kobayashi, N.; Kubota, K.; Saito, S.; Matsuhashi, N.; Nakajima, A. Incidence of small bowel injury induced by low-dose aspirin: a cross over study using capsule endoscopy in healthy volunteers. Digestion, 2009, 79, 44-51.
14. Wallace, J.L.; Del Soldato, P. The therapeutic potential of NO-NSAIDs. Fundam. Clin. Pharmacol., 2003, 17, 11-20. (Pubitemid 36241449)
15. Wallace, J.L.; Vong, L. NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs. Curr. Opin. Investig. Drugs, 2008, 9, 1151-1156.
16. Wallace, J.L.; Viappiani, S.; Bolla, M. Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis. Trends Pharmacol. Sci., 2009, 30, 112-117.
17. Takeuchi, K.; Mizoguchi, H.; Araki, H.; Komoike, Y.; Suzuki, K. Lack of gastric toxicity of nitric oxide releasing indomethacin, NC-530, in experimental animals. Dig. Dis. Sci., 2001, 46, 1805-1818. (Pubitemid 32727118)
18. Mizoguchi, H.; Hase, S.; Tanaka, A.; Takeuchi, K. Lack of small intestinal ulcerogenicity of nitric oxide-releasing indomethacin, NCX-530, in rats. Aliment. Pharmacol. Ther., 2001,15, 257-267.
19. Hawkey, C.J.; Jones, J.I.; Atherton, C.T.; Skelly, M.M.; Bebb, J.R.; Fagerholm, U.; Jonzon, B, Karlsson, P. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut, 2003, 52, 1537-1542. (Pubitemid 37363434)
20. Fiorucci, S.; Distrutti, E.; Cirino, G.; Wallace, J.L. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology, 2006, 131, 259-271. (Pubitemid 44043128)
21. Wallace, J.L.; Caliendo, G.; Santagada, V.; Cirino, G.; Fiorucci, S. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfidereleasing diclofenac in the rat. Gastroenterology, 2007, 132, 261-271. (Pubitemid 46108763)
22. Caliendo, G.; Cirino, G.; Santagada, V.; Wallace, J.L. Synthesis and biological effects of hydrogen sulfide (H2S): Development of H2S-releasing drugs as pharmaceuticals. J. Med. Chem., 2010, 53, 6275-6286.
23. Wallace, J.L.; Caliendo, G.; Santagada, V.; Cirino, G. Markedly reduced toxicity of a hydrogen sulfide-releasing naproxen (ATB-346). Br. J. Pharmacol., 2010, 159, 1236-1246.
24. Rossoni, G.; Manfredi, B.; Del Soldato, P.; Berti, F. The nitric oxidereleasing naproxen derivative displays cardioprotection in perfused rabbit heart submitted to ischemia-reperfusion. J. Pharmacol. Exp. Ther., 2004 310, 555-562. (Pubitemid 38988899)
25. Rossoni, G.; Sparatore, A.; Tazzari, V.; Manfredi, B.; Del Soldato, P.; Berti, F. The hydrogen sulfide-releasing derivative of diclofenac protects against ischemia-reperfusion injury in the isolated rabbit heart. Br. J. Pharmacol., 2008 153, 100-109.
26. Lichtenberger, L.M., Barron, M., Marathi, U. Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. Drugs Today, 2009, 45, 877-890.
27. Lichtenberger, L.M.; Romero J.J.; Dial E.J.; Moore J.E. Naproxen-PC: A GI safe and highly effective anti-inflammatory. Inflammopharmacology, 2009, 17, 1-5.
28. Lichtenberger, L.M.; Romero, J.J.; Dial, E.J. Gastrointestinal safety and therapeutic efficacy of parenterally administered phosphatidylcholineassociated indomethacin in rodent model systems. Br. J. Pharmacol., 2009, 157, 252-257.
29. Lanza, F.L.; Marath, U.K.; Anand, B.S.; Lichtenberger, L.M. Clinical trial: Comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. Aliment. Pharmacol. Ther., 2008, 28, 431-442. (Pubitemid 352033288)
30. Cryer, B.; Bhatt, D.L.; Lanza, F.L.; Dong, J.F. Lichtenberger, L.M.; Marathi, U.K. Low dose aspirin-induced ulceration is attenuated by aspirinphosphatidylcholine; A randomized clinical trial. Am. J. Gastroenterol., 2011, 106, 272-277.
31. Bjarnason, I.; Smethurst, P.; Fenn, C.G.; Lee, C.H.; Menzies, I.S.; Levi, A.J. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig. Dis. Sci., 1989, 34, 407-411. (Pubitemid 19088782)
32. Watanabe, T.; Sugimori, S.; Kameda, S.; Machida, H.; Okazaki, H.; Tanigawa, T.; Watanabe, K.; Tominaga, K.; Fujiwara, Y.; Oshitani, N.; Higuchi, K.; Arakawa, T. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin. Gastroenterol. Hepatol., 2008, 6, 1279-1282.
33. Fujimori, S.; Seo, T.; Gudis, K.; Ehara, A.; Kobayashi, T.; Mitsui, K.; Yonezawa, M.; Tanaka, S.; Tatsuguchi, A.; Sakamoto, C. Prevention of nonsteroidal anti-inflammatory drug-induced small intestinal injury by prostaglandin: a pilot randaomized controlled trial evaluated by capsule endoscopy. Gastrointest. Endosc., 2009, 69, 1339-1346.
34. Naito, Y., Yoshikawa, T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities, Expert Rev. Gastroenterol. Hepathol., 2010, 4, 261-270.
35. Park, S-H.; Cho, C-S.; Lee, O-Y.; Jun, J-B.; Lin, S-R.; Zhou, L-Y.; Yuan, YZ.; Li, Z-S.; Hou, X-H.; Zhao, H-C.; Kachintorn, U.; Kositchaiwat, C.; Lertkupinit, C. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM study. J. Clin. Biochem. Nutr., 2007, 40, 148-155. (Pubitemid 46623817)
36. Mizoguchi, H.; Ogawa, Y.; Kanatsu, K.; Tanaka, A.; Kato, S.; Takeuchi, K. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J. Gastroenterol. Hepatol., 2001, 16, 1112-1119. (Pubitemid 32990106)
37. Niwa, Y.; Nakamura, M.; Ohmiya, N.; Maeda, O.; Ando, T.; Ito, A.; Hirooka, Y.; Goto, H. Efficacy of rebamipide for diclofenac-induced smallintestinal mucosal injuries in healthy subjects: a prospective, randaomized, double-blinded, placebo-controlled, cross-over study. J. Gastroenterol., 2008, 43, 270-276. (Pubitemid 351650037)
38. Fujimori, S.; Takahashi, Y.; Gudis, K.; Seo, T.; Ehara, A.; Kobayashi, T.; Mitsui, K.; Yonezawa, M.; Tanaka, S.; Tatsuguchi, A.; Sakamoto, C. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J. Gastoenterol., 2011, 46, 57-64.
39. Nishida, U., Kato, M., Nishida, M., Kamada, G., Yoshida, T., Ono, S., Shimizu, Y., Asaka, M. Evaluation of small bowel blood flow in healthy subjects receiving low-dose aspirin. World J. Gastroenterol., 2011, 17, 226-230.
40. Yanaka, A.; Zhang, S.; Sato, D.; Tauchi, M.; Suzuki, H.; Shibahara, T.; Matsui, H.; Nakahara, A.; Hyodo, I. Geranylgeranylacetone protects the human gastric mucosa from diclofenac-induced injury via induction of heat shock protein 70. Digestion, 2007, 75, 148-155. (Pubitemid 47343972)
41. Asano, T.; Tanaka, K.; Yamakawa, N.; Adachi, H.; Sobue, G.; Goto, H.; Takeuchi, K.; Mizushima, T. HSP70 confers protection against indomethacin-induced lesions of the small intestine. J. Pharmacol. Exp. Ther., 2009, 330, 458-467.
42. Iwai, T.; Ichikawa, T.; Kida, M.; Goso, Y.; Kurihara, M.; Koizumi, W.; Ishihara, K. Protective effect of geranylgeranylacetone against loxoprofen sodium-induced small intestinal lesions in rats. Eur. J. Pharmacol., 2011, 652, 121-125.
43. Niwa, Y.; Nakamura, M.; Miyahara, R.; Ohmiya, N.; Watanabe, O.; Ando, T.; Kawashima, H.; Ito, A.; Hirooka, Y.; Goto, H. Geranylgeranylacetone protects against diclofenac-induced gastric and small-intestinal mucosal injuries in healthy subjects: a prospective, randaomized, placebo-controlled, double-blinded, cross-over study. Digestion, 2009, 80, 260-266.
44. Shiotani, A.; Haruma, K.; Nishi, R.; Fujita, M.; Kamada, T.; Honda, K.; Kusunoki, H.; Hata, J.; Graham, D.Y. Randamized, double-blind, pilot study of geranyl-geranylaceton versus placebo in patients taking low-dose entericcoated aspirin. Low-dose aspirin-induced small bowel damage. Scand. J. Gastroenterol., 2010, 45, 292-298.
45. Ito, M.; Tanaka, T.; Suzuki Y. Effect of N-(3-aminopropinyl)-L- histidinato zinc (Z-103) on healing and hydrocortisone-induced relapse of acetic acid ulcers in rats with limited food-intake-time. Jpn. J. Pharmacol., 1990, 52, 513-521. (Pubitemid 20127309)
46. Ueda, K.; Ueyama, T.; Oka, M.; Ito, T.; Tsuruo, Y.; Ichinose, M. Polaprezinc (Zinc L-carnosine) is a potent inducer of anti-oxidative stress enzyme, heme oxygenase (HO)-1: a new mechanism of gastric mucosal protection. J. Pharmacol. Sci., 2009, 110, 285-294.
47. Omatsu, T.; Naito, Y.; Handa, O.; Mizushima, K.; Hayashi, N.; Qin, Y.; Harusato, A.; Hirata, I.; Kishimoto, E.; Okada, H.; Uchiyama, K.; Ishikawa, T.; Takagi, T.; Yagi, N.; Kokura, S.; Ichikawa, H.; Yoshikawa, T. Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury. J. Gastroenterol., 2010, 45, 692-702.
48. Mahmood, A.; FitzGerald, A.J.; Marchbank, T.; Ntatsaki, E.; Murray, D.; Ghosh, S.; Playford, R.J. Zinc carnosine, a health food supplement that stabilizes small bowel integrity and stimulates gut repair processes. Gut, 2007, 56, 168-175.
49. Ueda, F.; Ban, K.; Ishima, T. Irsogladine activates gap-junctional intracellular communication through M1 muscarinic acetylcholine receptor. J. Pharmacol. Exp. Ther., 1995, 274, 815-819.
50. Kamei, K.; Kubo, Y.; Kato, N.; Hatazawa, R.; Amagase, K.; Takeuchi, K. Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats. Dig. Dis. Sci., 2008, 53, 2657-2666.
51. Satoh, H.; Inatomi, N.; Nagaya, H.; Inada, I.; Nohara, A.; Nakamura, N.; Maki, Y. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J. Pharmacol. Exp. Ther., 1989, 248, 806-815. (Pubitemid 19090258)
52. Kuroda, M.; Yoshida, N.; Ichikawa, H.; Takagi, T.; Okuda, T.; Naito, Y.; Okanoue, T.; Yoshikawa, T. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int. J. Mol. Med., 2006, 17, 89-93.
53. Pozzoli, C.; Menozzi, A.; Grandi, D.; Soleghi, E.; Ossiprandi, M.C.; Zullian, C.; Bertini, S.; Cavestro, G.M.; Coruzzi, G. Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine. Naunyn-Schmiedberg's Arch Pharmacol., 2007, 374, 283-291. (Pubitemid 46089466)
54. Takagi, T.; Naito, Y.; Yoshikawa, T. The expression of heme oxygenase-1 induced by lansoprazole. J. Clin. Biochem. Nutr., 2009, 45, 9-13.
55. Yoda, Y.; Amagase, K.; Kato, S.; Tokioka, S.; Maruno, M.; Kakimoto, K.; Nishio, H.; Umegaki, E.; Takeuchi, K.; Higuchi K. Prevention by lansoprazole, a proton pump inhibitor, of indomethacin-induced small intestinal ulceration in rats through induction of heme oxygenase-1. J. Physiol. Pharmacol., 2010, 61, 287-294.
56. Satoh, H.; Amagase, K.; Takeuchi, K. Antisecretory drugs aggravate small intestinal lesions induced by NSAIDs in rats. Gastroenterology, 2011, 140 (suppl 1), S-192.
57. Wallace, J.L.; Denou, E.; Syer, S.; Vong, L.; McKnight, W.; Jury, J.; Bolla, M.; Bercik, P.; Collins, S.; Verdu, E.; Ongini, E. Proton pump inhibitors and low-dose aspirin markedly exacerbate NSAID-induced small intestinal injury. Gastroenterology, 2011, 140 (suppl 1), S-87.
58. Shibata, M.; Yamamura, T.; Inaba, N.; Onodera, S.; Chiba, Y.; Ohnishi, H. Gastric antisecretory effect of FRG-8813, a new histamine H2 receptor antagonist, in rats and dogs. Eur. J. Pharmacol., 1993, 235, 243-253.
59. Onodera, S.; Shibata, M.; Tanaka, M.; Inaba, N.; Yamamura, T.; Ohnishi, H. Gastroprotective activity of FRG-8813, a novel histamine H2 receptor antagonist, in rats. Jpn. J. Pharmacol., 1995, 68, 161-173.
60. Kato, S.; Tanaka, A.; Kunikata, T.; Umeda, M.; Takeuchi, K. Protective effect of lafutidine against indomethacin-induced intestinal ulceration in rats: Relation to capsaicin-sensitive sensory neurons. Digestion, 2000, 61, 39-46. (Pubitemid 30098957)
61. Tanaka, A.; Mizoguchi, H.; Hase, S.; Miyazawa, T.; Takeuchi, K. Intestinal protection by lafutidine, a histamine H2-receptor antagonist, against indomethacin-induced damage in rats-role of endogenous nitric oxide. Med. Sci. Monit., 2001, 7, 869-877. (Pubitemid 32928602)
62. Amagase, K.; Ochi, A.; Sugihara, T.; Kato, S.; Takeuchi, K. Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats. J. Gastroenterol. Hepatol., 2010, 25 (suppl 1), S111-S118.
63. Sekine, Y.; Hirakawa, N.; Kashiwaba, N.; Matsumoto, H.; Kutsuma, T.; Yamaura, T.; Sekine A. A novel histamine H2 receptor antagonist with gastroprotective activity. I. Synthesis and pharmacological evaluation of Nphenoxypropylacetamide derivatives with thioether function. Chem. Pharma. Bull. (Tokyo) 1998, 46, 610-615. (Pubitemid 28216935)
64. Ichikawa, T.; Ishihara, K.; Saigenji, K.; Hotta, K. Structural requirements for roxatidine in the stimulant effect of rat gastric mucin synthesis and the participation of nitric oxide in this mechanism. Br. J. Pharmacol., 1997, 122, 1230-1236. (Pubitemid 27494241)
65. Umegaki, E.; Yoda, Y.; Tokioka, S.; Murano, M.; Higuchi K. Protective effect of roxatidine against indomethacin-induced small intestinal mucosal injury in rats. J. Gastroenterol. Hepatol., 2010, 25 (suppl 1), S35-S40.
66. Robert, A.; Asano, T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins, 1977, 14, 333-341. (Pubitemid 8171147)
67. Lanas, A.; Scarpignato, C. Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? Digestion, 2006, 73 (suppl 1), 136-150.
68. Bjarnason, I.; Hayllar, J.; Smethurst, P.; Price A.; Gumpel M.J. Metronidazole reduces intestinal inflammation and blood loss in nonsteroidal anti-inflammatory drug induced enteropathy. Gut, 1992, 33, 1204-1208.
69. Davies, G.R.; Wilkie, M.E.; Rampton, D.S. Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig. Dis. Sci., 1993, 38, 417-425. (Pubitemid 23087113)
70. Scarpignato, C. NSAID-induced intestinal damage: are luminal bacteria the therapeutic target? Gut, 2008, 57, 145-148. (Pubitemid 351158035)
71. Gotteland, M.; Cruchet, S.; Verbeke, S. Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indomethacin in humans. Aliment. Pharmacol. Ther., 2001, 15, 11-17. (Pubitemid 32055581)
72. Kamil, R.; Geier, M.S.; Butler, R.N.; Howarth, G.S. Lactobacillus rhamnosus GG exacerbates intestinal ulceration in a model of indomethacininduced enteropathy. Dig. Dis. Sci., 2007, 52, 1247-1252. (Pubitemid 46626177)
73. Watanabe, T.; Nishio, H.; Tanigawa, T.; Yamagami, H.; Okazaki, H.; Wtanabe, K.; Tominaga, K.; Fujiwara, Y.; Oshitani, N.; Asahara, T.; Nomoto, K.; Higuchi, K.; Takeuchi, K.; Arakawa, T. Probiotic Lactbacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 297, G506-G513.
74. Satoh, H. Role of dietary fiber in formation and prevention of small intestinal ulcers induced by nonsteroidal anti-inflammatory drug. Curr. Pharm. Des., 2010, 16, 1209-1213
75. Dial, E.J.; Dohrman, A.J.; Romero, J.J.; Lichtenberger, LM. Recombinant human lactoferrin prevents NSAID-induced intestinal bleeding in rodents. J. Pharm. Pharmacol., 2005, 57, 93-99. (Pubitemid 40030107)
76. Troost, F.J.; Saris, W.H.; Brummer, R.J. Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers. Eur. J. Clin. Nutr., 2003, 57, 1579-1585. (Pubitemid 38016591)
77. Satoh, H.; Shiotani, S.; Otsuka, N.; Hatao, K.; Nishimura S. Role of dietary fibres, intestinal hypermotility and leukotrienes in the pathogenesis of NSAID-induced small intestinal ulcers in cats. Gut, 2009, 58, 1590-1596.
78. Takeuchi, K.; Miyazawa, T.; Tanaka, A.; Kato, S.; Kunikata, T. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion, 2002, 66, 30-41. (Pubitemid 36151288)
79. Satoh, H.; Hara, T.; Murakawa, D.; Matsuura, M.; Takata, K. Soluble dietary fiber protects against nonsteroidal anti-inflammatory drug-induced damage to the small intestine in cats. Dig. Dis. Sci., 2010, 55, 1264-1271.
80. Watanabe, T.; Higuchi, K.; Kobata, A.; Nishio, H.; Tanigawa, T.; Shibata, M.; Tominaga, K.; Fujiwara, Y.; Oshitani, N.; Asahara, T.; Nomoto, K.; Takeuchi, K.; Arakawa, T. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut, 2008, 57, 181-187. (Pubitemid 351158044)
81. Takeuchi, K.; Tanigami, M.; Amagase, K.; Ochi, A.; Okuda, S.; Hatazawa, R. Endogenous prostaglandin E2 accelerates healing of indomethacininduced small intestinal lesions through upregulation of vascular endothelial growth factor expression by activation of EP4 receptors. J. Gastroenterol. Hepatol., 2010, 25 (suppl 1), S67-S74